Celanese Q3 2026 earnings beat and raises full-year outlook
- Q3 U.S. GAAP diluted EPS $0.68 and adjusted EPS $1.65 on net sales of $2.6 billion, up 6% year‑over‑year and down 7% sequentially.
- Consolidated operating profit $198 million, adjusted EBIT $367 million and operating EBITDA $548 million, with margins of 8%, 14% and 21% respectively.
- Q3 operating cash flow $538 million and free cash flow $461 million; year‑to‑date free cash flow $604 million and management expects over $1.5 billion FCF across the past two years by year‑end.
- Raised full‑year adjusted EPS guidance to approximately $6.00–$6.25 and increased free cash flow outlook to $750–$800 million; expects net debt-to-operating EBITDA of ~4.7x at year‑end and divestiture proceeds of ~ $650 million by year‑end toward a $1 billion target by end‑2027.
Quarter results
Celanese reported third quarter 2026 U.S. GAAP diluted EPS of $0.68 and adjusted EPS of $1.65, with net sales of $2.6 billion, up 6% year‑over‑year and down 7% sequentially. Consolidated operating profit was $198 million, adjusted EBIT $367 million, and operating EBITDA $548 million, with margins of 8%, 14% and 21% respectively.
Segment performance
Engineered Materials posted net sales of $1.4 billion, down 1% year‑over‑year (including the prior Micromax divestiture); operating profit was $161 million, adjusted EBIT $209 million, and operating EBITDA $311 million with margins of 12%, 15% and 23%. Management cited mix enrichment from medical and electronics and said three targeted expansion projects are on track to commercialize in the first half of 2027. The Acetyl Chain reported net sales of $1.2 billion, up 14% year‑over‑year, with operating profit $141 million, adjusted EBIT $236 million and operating EBITDA $301 million, and margins of 12%, 20% and 25% supported by pricing and spot opportunities.
Cash flow, tax and balance sheet
Third quarter operating cash flow was $538 million and free cash flow $461 million; year‑to‑date operating cash flow was $823 million and free cash flow $604 million. The effective U.S. GAAP tax rate for Q3 was 15% and the adjusted effective tax rate was 8%, which management expects for the full year. Management expects to have generated over $1.5 billion in free cash flow across the past two years by year‑end and to exit 2026 with net debt‑to‑operating EBITDA of approximately 4.7x.
Corporate actions and outlook
Celanese signed an agreement to sell an additional 19% of the Nutrinova joint venture to Mitsui for approximately $152 million, retaining an 11% interest and expecting the transaction to close in Q4 2026. The company added a board member, entered a strategic partnership with VIGOR Precision on lightweight plastic robot joints, and completed closure of an acetate tow facility in Belgium. Management raised full‑year adjusted EPS guidance to about $6.00–$6.25 and increased free cash flow guidance to $750–$800 million, and continues to target approximately $1 billion of divestiture proceeds by the end of 2027.
Source: Celanese